On October 9, 2025, the VERBA LEGAL team successfully completed support for the additional share issue of Ozon Pharmaceutics PJSC (“the Company”), a leading Russian pharmaceutical group. This step marked the final stage of the secondary public offering (SPO) conducted by the Company on June 20, 2025, under VERBA LEGAL’s advisory.

The transaction was implemented in a top-up format, involving capital raising in two stages: the SPO (June 20, 2025) and the additional issue (placement completed on October 9, 2025).

The funds raised during the SPO allowed Ozon LLC to repurchase shares to repay a securities loan to the Company’s founder. As a result, the founder’s shareholding returned to the pre-SPO level, while the Company received additional cash inflows.

During the additional issue, 3.2 million shares were also offered to existing shareholders who exercised their preemptive rights, allowing them to maintain their proportional ownership in the Company and purchase the newly issued shares at the SPO price.

The VERBA LEGAL team on the project included Partner Alexander Kuznetsov, Senior Associate Anna Sidorenko, Associate Ivan Dubrovsky, and Senior Associate of the Tax Advisory & Disputes practice Andrey Sheptiy.